US3524595A
(en)
*
|
1964-10-26 |
1970-08-18 |
Kewanee Mach & Conveyor Co |
Processing apparatus
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
GB1458148A
(en)
|
1974-04-19 |
1976-12-08 |
Wyeth John & Brother Ltd |
Carbocyclic-fused ring quinoline derivatives
|
JPS57123267A
(en)
|
1981-01-23 |
1982-07-31 |
Kansai Paint Co Ltd |
Thermosetting paint composition
|
JPS5944869U
(ja)
|
1982-09-17 |
1984-03-24 |
近畿アルミニユ−ム工業株式会社 |
プレートの間隔修正工具を備えた蝶番
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
EP0154434B1
(en)
|
1984-02-17 |
1993-01-27 |
Genentech, Inc. |
Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods
|
US4582789A
(en)
|
1984-03-21 |
1986-04-15 |
Cetus Corporation |
Process for labeling nucleic acids using psoralen derivatives
|
DE8411409U1
(de)
|
1984-04-11 |
1984-08-30 |
Dr.-Ing. Walter Frohn-Betriebe, 8000 München |
Entgasungsventil fuer lager- und/oder transportbehaelter
|
US4563417A
(en)
|
1984-08-31 |
1986-01-07 |
Miles Laboratories, Inc. |
Nucleic acid hybridization assay employing antibodies to intercalation complexes
|
EP0183858B1
(de)
|
1984-11-22 |
1988-09-14 |
Holsten-Brauerei AG |
Bier und Verfahren zu dessen Herstellung
|
ATE92499T1
(de)
|
1984-12-04 |
1993-08-15 |
Lilly Co Eli |
Tumorbehandlung bei saeugetieren.
|
JPS61148115A
(ja)
|
1984-12-21 |
1986-07-05 |
Tooa Eiyoo Kk |
難溶性薬物の徐放性製剤及びその製造法
|
JPS62168137A
(ja)
|
1985-12-20 |
1987-07-24 |
Fuji Photo Film Co Ltd |
ハロゲン化銀カラ−写真感光材料およびその処理方法
|
CH656535A5
(en)
|
1986-01-24 |
1986-07-15 |
Spirig Ag |
Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water
|
JPH07106295B2
(ja)
|
1986-07-22 |
1995-11-15 |
エーザイ株式会社 |
調湿剤
|
JPS62123193A
(ja)
|
1986-11-13 |
1987-06-04 |
Asahi Chem Ind Co Ltd |
テトラアザアヌレン類のコバルト化合物の製造方法
|
US4743450A
(en)
|
1987-02-24 |
1988-05-10 |
Warner-Lambert Company |
Stabilized compositions
|
CA1339136C
(en)
|
1987-07-01 |
1997-07-29 |
Sailesh Amilal Varia |
Amorphous form of aztreonam
|
US5009894A
(en)
|
1988-03-07 |
1991-04-23 |
Baker Cummins Pharmaceuticals, Inc. |
Arrangement for and method of administering a pharmaceutical preparation
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US4983615A
(en)
|
1989-06-28 |
1991-01-08 |
Hoechst-Roussel Pharmaceuticals Inc. |
Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
|
JPH0340486A
(ja)
|
1989-07-07 |
1991-02-21 |
Asahi Chem Ind Co Ltd |
印刷配線基板
|
EP0408496A3
(en)
|
1989-07-12 |
1992-07-01 |
Ciba-Geigy Ag |
Solid dosage form for pharmaceutical substances
|
JP2980326B2
(ja)
|
1989-08-31 |
1999-11-22 |
株式会社東芝 |
ディスク制御装置
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
US5180818A
(en)
|
1990-03-21 |
1993-01-19 |
The University Of Colorado Foundation, Inc. |
Site specific cleavage of single-stranded dna
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
EP0834576B1
(en)
|
1990-12-06 |
2002-01-16 |
Affymetrix, Inc. (a Delaware Corporation) |
Detection of nucleic acid sequences
|
GB9105677D0
(en)
|
1991-03-19 |
1991-05-01 |
Ici Plc |
Heterocyclic compounds
|
US5367057A
(en)
|
1991-04-02 |
1994-11-22 |
The Trustees Of Princeton University |
Tyrosine kinase receptor flk-2 and fragments thereof
|
EP0584222B1
(en)
|
1991-05-10 |
1997-10-08 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
US5721237A
(en)
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
JPH04341454A
(ja)
|
1991-05-16 |
1992-11-27 |
Canon Inc |
シート収納装置
|
US5750376A
(en)
|
1991-07-08 |
1998-05-12 |
Neurospheres Holdings Ltd. |
In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
|
US5211951A
(en)
|
1991-07-24 |
1993-05-18 |
Merck & Co., Inc. |
Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
|
JPH05194259A
(ja)
|
1991-08-30 |
1993-08-03 |
Mitsubishi Kasei Corp |
抗消化性潰瘍剤
|
US5200194A
(en)
|
1991-12-18 |
1993-04-06 |
Alza Corporation |
Oral osmotic device
|
EP0648264A4
(en)
|
1992-06-03 |
1997-10-01 |
Univ Case Western Reserve |
BANDAGE ALLOWING THE CONTINUOUS APPLICATION OF ORGANIC PRODUCTS.
|
TW271400B
(ar)
|
1992-07-30 |
1996-03-01 |
Pfizer |
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
JPH06153952A
(ja)
|
1992-11-26 |
1994-06-03 |
Nobuaki Tamamaki |
微量未知二重鎖dna分子の増幅、標識を行うための前処理方法
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
ES2133158T3
(es)
|
1993-01-19 |
1999-09-01 |
Warner Lambert Co |
Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
|
US6027880A
(en)
|
1995-08-02 |
2000-02-22 |
Affymetrix, Inc. |
Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
JPH07176103A
(ja)
|
1993-12-20 |
1995-07-14 |
Canon Inc |
光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体
|
GB9326136D0
(en)
|
1993-12-22 |
1994-02-23 |
Erba Carlo Spa |
Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
JP3660391B2
(ja)
|
1994-05-27 |
2005-06-15 |
株式会社東芝 |
半導体装置の製造方法
|
JPH0848078A
(ja)
|
1994-08-05 |
1996-02-20 |
Nippon Paper Ind Co Ltd |
感熱記録体
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
US5656454A
(en)
|
1994-10-04 |
1997-08-12 |
President And Fellows Of Harvard College |
Endothelial cell-specific enhancer
|
JP3207058B2
(ja)
|
1994-11-07 |
2001-09-10 |
財団法人国際超電導産業技術研究センター |
超電導体薄膜及びその製造方法
|
IL115256A0
(en)
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
JPH08176138A
(ja)
|
1994-12-19 |
1996-07-09 |
Mercian Corp |
イソクマリン誘導体
|
US5948438A
(en)
|
1995-01-09 |
1999-09-07 |
Edward Mendell Co., Inc. |
Pharmaceutical formulations having improved disintegration and/or absorptivity
|
US5658374A
(en)
|
1995-02-28 |
1997-08-19 |
Buckman Laboratories International, Inc. |
Aqueous lecithin-based release aids and methods of using the same
|
US5624937A
(en)
|
1995-03-02 |
1997-04-29 |
Eli Lilly And Company |
Chemical compounds as inhibitors of amyloid beta protein production
|
US6579314B1
(en)
|
1995-03-10 |
2003-06-17 |
C.R. Bard, Inc. |
Covered stent with encapsulated ends
|
WO1996030347A1
(en)
|
1995-03-30 |
1996-10-03 |
Pfizer Inc. |
Quinazoline derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US5654005A
(en)
|
1995-06-07 |
1997-08-05 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation having a preformed passageway
|
DE69531558T2
(de)
|
1995-06-07 |
2004-03-18 |
Pfizer Inc. |
Heterocyclische kondensierte pyrimidin-derivate
|
JPH0923885A
(ja)
|
1995-07-12 |
1997-01-28 |
Dai Ichi Seiyaku Co Ltd |
遺伝子発現ライブラリー及びその製造法
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
US6346398B1
(en)
|
1995-10-26 |
2002-02-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
|
JP4009681B2
(ja)
|
1995-11-07 |
2007-11-21 |
キリンファーマ株式会社 |
血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
|
US5849759A
(en)
|
1995-12-08 |
1998-12-15 |
Berlex Laboratories, Inc. |
Naphthyl-substituted benzimidazole derivatives as anti-coagulants
|
GB9604361D0
(en)
|
1996-02-29 |
1996-05-01 |
Pharmacia Spa |
4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
|
JPH09234074A
(ja)
|
1996-03-04 |
1997-09-09 |
Sumitomo Electric Ind Ltd |
アダプター二本鎖dna及びそれを用いたdna増幅方法
|
EP0960104B1
(en)
|
1996-04-17 |
2004-06-16 |
Bristol-Myers Squibb Pharma Company |
N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
|
AU3568897A
(en)
|
1996-06-07 |
1998-01-05 |
Eos Biotechnology, Inc. |
Immobilised linear oligonucleotide arrays
|
EP0912175A4
(en)
|
1996-06-28 |
1999-09-08 |
Merck & Co Inc |
FIBRINOGENIC RECEPTOR ANTAGONISTS
|
DE69716916T2
(de)
|
1996-07-13 |
2003-07-03 |
Glaxo Group Ltd |
Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
BR9710362A
(pt)
|
1996-07-13 |
1999-08-17 |
Glaxo Group Ltd |
Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
|
JPH10147524A
(ja)
|
1996-09-20 |
1998-06-02 |
Nippon Kayaku Co Ltd |
フォルスコリン誘導体含有経口製剤及び医薬製剤の製法
|
EP0929526B1
(en)
|
1996-09-25 |
2005-07-27 |
AstraZeneca AB |
Qinoline derivatives inhibiting the effect of growth factors such as vegf
|
AU725138B2
(en)
|
1996-09-30 |
2000-10-05 |
Nihon Nohyaku Co., Ltd. |
1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
|
JPH10114655A
(ja)
|
1996-10-09 |
1998-05-06 |
Kyowa Hakko Kogyo Co Ltd |
固形製剤
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
JP2000505109A
(ja)
|
1996-11-27 |
2000-04-25 |
ファイザー・インク |
縮合二環式ピリミジン誘導体
|
TW486370B
(en)
|
1996-12-25 |
2002-05-11 |
Yamanouchi Pharma Co Ltd |
Rapidly disintegrable pharmaceutical composition
|
CA2275777A1
(en)
|
1997-01-29 |
1998-07-30 |
Louise Richman Levine |
Treatment for premenstrual dysphoric disorder
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
JP3040486U
(ja)
|
1997-02-13 |
1997-08-19 |
有限会社ザップ |
フィッシングジャケット
|
ATE345339T1
(de)
|
1997-02-19 |
2006-12-15 |
Berlex Lab |
N-heterocyclische derivate als nos inhibitoren
|
US6090556A
(en)
|
1997-04-07 |
2000-07-18 |
Japan Science & Technology Corporation |
Method for quantitatively determining the expression of a gene
|
AU7526798A
(en)
|
1997-04-18 |
1998-11-27 |
Smithkline Beecham Plc |
Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
|
JPH10316576A
(ja)
|
1997-05-13 |
1998-12-02 |
Nissui Pharm Co Ltd |
キトサン含有錠剤
|
JP4344960B2
(ja)
|
1997-05-23 |
2009-10-14 |
バイエル、コーポレイション |
アリール尿素によるp38キナーゼ活性の阻害
|
BR9714787A
(pt)
|
1997-06-10 |
2000-07-18 |
Synthon Bv |
Compostos de 4- fenilpiperidina e processo para sua preparação
|
US6093742A
(en)
|
1997-06-27 |
2000-07-25 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of p38
|
WO1999001738A2
(en)
|
1997-06-30 |
1999-01-14 |
University Of Maryland, Baltimore |
Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
|
BE1011251A3
(fr)
|
1997-07-03 |
1999-06-01 |
Ucb Sa |
Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
JP3765918B2
(ja)
|
1997-11-10 |
2006-04-12 |
パイオニア株式会社 |
発光ディスプレイ及びその駆動方法
|
JP4194678B2
(ja)
|
1997-11-28 |
2008-12-10 |
キリンファーマ株式会社 |
キノリン誘導体およびそれを含む医薬組成物
|
NZ505844A
(en)
|
1997-12-22 |
2003-10-31 |
Bayer Ag |
Inhibition of raf kinase using substituted heterocyclic ureas
|
DE69829412T2
(de)
|
1997-12-22 |
2005-07-28 |
Bayer Pharmaceuticals Corp., West Haven |
Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
|
DE69836563T2
(de)
|
1997-12-22 |
2007-05-16 |
Bayer Pharmaceuticals Corp., West Haven |
INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
|
DE1041982T1
(de)
|
1997-12-22 |
2001-06-07 |
Bayer Ag |
HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
ID26250A
(id)
|
1998-02-25 |
2000-12-07 |
Genetics Inst |
Inhibitor-inhibitor dari enzim-enzim fosfolipase
|
JP2002505269A
(ja)
|
1998-03-06 |
2002-02-19 |
エウランド インターナショナル ソシエタ ペル アチオニ |
急速崩壊錠剤
|
DE19814257A1
(de)
|
1998-03-31 |
1999-10-07 |
Asta Medica Ag |
Brauseformulierungen
|
JPH11322596A
(ja)
|
1998-05-12 |
1999-11-24 |
Shionogi & Co Ltd |
白金錯体および環状リン酸エステルアミドを含有する抗癌剤
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
US6653341B1
(en)
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
CA2755266C
(en)
|
1998-06-17 |
2014-08-12 |
Eisai R&D Management Co., Ltd. |
Intermediates for preparing macrocyclic analogs
|
US8097648B2
(en)
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
ATE286725T1
(de)
|
1998-10-01 |
2005-01-15 |
Novartis Pharma Gmbh |
Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
|
GEP20032997B
(en)
|
1998-11-19 |
2003-06-25 |
Warner Lambert Co |
N-[4-(3-Chloro-4-Fluoro-Phenylamino)-7-(3-Morpholin-4-Yl-Propoxy)-Quinazolin-6-Yl]-crylamide, as an Irreversible Inhibitor of Tyrosine Kinases
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6797823B1
(en)
|
1999-01-22 |
2004-09-28 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
PT1154774E
(pt)
|
1999-02-10 |
2005-10-31 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores de angiogenese
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
JP2000328080A
(ja)
|
1999-03-12 |
2000-11-28 |
Shin Etsu Chem Co Ltd |
シートベルト用低摩擦化処理剤
|
YU13200A
(sh)
|
1999-03-31 |
2002-10-18 |
Pfizer Products Inc. |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
US6416758B1
(en)
|
1999-04-28 |
2002-07-09 |
Board Of Regents, The University Of Texax System |
Antibody conjugate kits for selectively inhibiting VEGF
|
WO2000071097A1
(fr)
|
1999-05-20 |
2000-11-30 |
Takeda Chemical Industries, Ltd. |
Composition contenant du sel d'acide ascorbique
|
JP4304357B2
(ja)
|
1999-05-24 |
2009-07-29 |
独立行政法人理化学研究所 |
完全長cDNAライブラリーの作成法
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
JP2001047890A
(ja)
|
1999-08-06 |
2001-02-20 |
Toyota Motor Corp |
車両用パワープラントの制御装置
|
WO2001012600A1
(en)
|
1999-08-12 |
2001-02-22 |
Cor Therapeutics, Inc. |
INHIBITORS OF FACTOR Xa
|
CO5200835A1
(es)
|
1999-09-28 |
2002-09-27 |
Bayer Corp |
Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
|
US6762180B1
(en)
|
1999-10-13 |
2004-07-13 |
Boehringer Ingelheim Pharma Kg |
Substituted indolines which inhibit receptor tyrosine kinases
|
UA75054C2
(uk)
|
1999-10-13 |
2006-03-15 |
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг |
Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
|
JP2001131071A
(ja)
|
1999-10-29 |
2001-05-15 |
Meiji Seika Kaisha Ltd |
非晶質および非晶質を含有する医薬組成物
|
WO2001032926A2
(en)
|
1999-11-01 |
2001-05-10 |
Curagen Corporation |
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
|
US20080241835A1
(en)
|
1999-11-01 |
2008-10-02 |
Genentech, Inc. |
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
|
MXPA02004879A
(es)
|
1999-11-16 |
2002-08-30 |
Boehringer Ingelheim Pharma |
Derivados de urea como agentes antiinflamatorios.
|
UA75055C2
(uk)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
PT1255536E
(pt)
|
1999-12-22 |
2006-09-29 |
Sugen Inc |
Derivados de indolinona para a modulacao da tirosina proteina cinase de tipo c-kit
|
AU2223201A
(en)
|
1999-12-24 |
2001-07-09 |
Kirin Beer Kabushiki Kaisha |
Quinoline and quinazoline derivatives and drugs containing the same
|
US7005430B2
(en)
|
1999-12-24 |
2006-02-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused purine derivatives
|
ATE369359T1
(de)
|
2000-02-15 |
2007-08-15 |
Sugen Inc |
Pyrrol substituierte indolin-2-on protein kinase inhibitoren
|
JP3657203B2
(ja)
|
2000-04-21 |
2005-06-08 |
エーザイ株式会社 |
銅クロロフィリン塩含有液剤組成物
|
CN1116047C
(zh)
|
2000-06-05 |
2003-07-30 |
华中科技大学 |
用泥鳅制成的护肝功能食品及其制备方法
|
EP1287029A2
(en)
|
2000-06-09 |
2003-03-05 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of colon cancer
|
AU2001277621A1
(en)
|
2000-08-09 |
2002-03-04 |
Astrazeneca Ab |
Antiangiogenic bicyclic derivatives
|
ES2318649T3
(es)
*
|
2000-10-20 |
2009-05-01 |
EISAI R&D MANAGEMENT CO., LTD. |
Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
|
TWI283575B
(en)
|
2000-10-31 |
2007-07-11 |
Eisai Co Ltd |
Medicinal compositions for concomitant use as anticancer agent
|
AU2002223684A1
(en)
|
2000-11-22 |
2002-06-03 |
Novartis Pharma Gmbh |
Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
|
US7238813B2
(en)
|
2000-11-29 |
2007-07-03 |
Smithkline Beecham Corporation |
Chemical compounds
|
US6544552B2
(en)
|
2001-01-11 |
2003-04-08 |
Particle And Coating Technologies, Inc. |
Method of producing porous tablets with improved dissolution properties
|
JP4808365B2
(ja)
|
2001-03-02 |
2011-11-02 |
ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
Pcr法
|
EP1490362A2
(en)
|
2001-03-08 |
2004-12-29 |
Millennium Pharmaceuticals, Inc. |
(homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases
|
BR0208627A
(pt)
|
2001-04-06 |
2004-03-09 |
Wyeth Corp |
Combinações antineoplásicas tal como rapamicina junto com gencitabina ou fluorouracila
|
JP2004536290A
(ja)
|
2001-04-19 |
2004-12-02 |
ゲゼルシャフト フュア バイオテクノロギッシェ フォーシュンク エム ベー ハー(ゲー ベー エフ) |
安定した、再生可能な抗体アレイの作製方法
|
NZ529046A
(en)
|
2001-04-27 |
2005-10-28 |
Kirin Brewery |
Quinoline derivative having azolyl group and quinazoline derivative
|
JP3602513B2
(ja)
|
2001-04-27 |
2004-12-15 |
麒麟麦酒株式会社 |
アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
|
JP2003026576A
(ja)
|
2001-05-09 |
2003-01-29 |
Eisai Co Ltd |
味覚改善製剤
|
US6812341B1
(en)
|
2001-05-11 |
2004-11-02 |
Ambion, Inc. |
High efficiency mRNA isolation methods and compositions
|
KR20080091866A
(ko)
|
2001-05-16 |
2008-10-14 |
노파르티스 아게 |
Ν-{5-[4-(4-메틸-피페라지노-메틸)-벤조일아미도]-2-메틸페닐}-4-(3-피리딜)-2-피리미딘-아민 및 화학치료제를 포함하는 배합물
|
WO2002096361A2
(en)
|
2001-05-30 |
2002-12-05 |
Sugen, Inc. |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
DE60233736D1
(de)
|
2001-06-22 |
2009-10-29 |
Kirin Pharma K K |
Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
|
US20030013208A1
(en)
|
2001-07-13 |
2003-01-16 |
Milagen, Inc. |
Information enhanced antibody arrays
|
GB0117144D0
(en)
|
2001-07-13 |
2001-09-05 |
Glaxo Group Ltd |
Process
|
JP4827154B2
(ja)
|
2001-07-25 |
2011-11-30 |
株式会社オーイズミ |
遊技装置
|
JP3088018U
(ja)
|
2001-08-02 |
2002-08-30 |
ユーエス工業株式会社 |
垂木支持用ブラケットを備えたパイプバンド
|
GB0119467D0
(en)
|
2001-08-09 |
2001-10-03 |
Smithkline Beecham Plc |
Novel compound
|
WO2003022028A2
(en)
|
2001-09-10 |
2003-03-20 |
Meso Scale Technologies, Llc |
Methods, reagents, kits and apparatus for protein function analysis
|
DE60228278D1
(de)
|
2001-09-20 |
2008-09-25 |
Ab Science |
Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
|
US20040266779A1
(en)
|
2001-09-27 |
2004-12-30 |
Anderson Kenneth C. |
Use of c-kit inhibitors for the treatment of myeloma
|
AU2002341881B2
(en)
|
2001-09-27 |
2008-05-08 |
Allergan, Inc. |
3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
|
JP2005531488A
(ja)
|
2001-10-09 |
2005-10-20 |
ザ・ユニバーシティ・オブ・シンシナティ |
甲状腺癌を処置するためのegf受容体阻害剤
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7658924B2
(en)
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
WO2003033472A1
(fr)
|
2001-10-17 |
2003-04-24 |
Kirin Beer Kabushiki Kaisha |
Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
|
CN1659145A
(zh)
|
2001-11-27 |
2005-08-24 |
惠氏控股公司 |
作为egf-r和her2激酶抑制剂的3-氰基喹啉
|
GB0201508D0
(en)
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
JP2003252737A
(ja)
|
2002-03-04 |
2003-09-10 |
Shin Etsu Chem Co Ltd |
口腔用組成物
|
EP1916001B1
(en)
|
2002-03-04 |
2011-05-25 |
Imclone LLC |
Human antibodies specific to KDR and uses thereof
|
EP1481678A4
(en)
|
2002-03-05 |
2009-12-30 |
Eisai R&D Man Co Ltd |
ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR
|
WO2003077842A2
(en)
|
2002-03-12 |
2003-09-25 |
Bristol-Myers Squibb Company |
Palatable oral suspension and method
|
JP2005520834A
(ja)
|
2002-03-20 |
2005-07-14 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
小細胞肺癌の同定、診断、および治療のための方法および組成物
|
US6790852B2
(en)
|
2002-04-18 |
2004-09-14 |
Hoffmann-La Roche Inc. |
2-(2,6-dichlorophenyl)-diarylimidazoles
|
AU2003235838A1
(en)
|
2002-05-01 |
2003-11-17 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
AU2003251968A1
(en)
|
2002-07-16 |
2004-02-02 |
Children's Medical Center Corporation |
A method for the modulation of angiogenesis
|
AU2003261238A1
(en)
|
2002-07-22 |
2004-02-09 |
Aspen Aerogels, Inc. |
Polyimide aerogels, carbon aerogels, and metal carbide aerogels and methods of making same
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
US7252976B2
(en)
|
2002-08-28 |
2007-08-07 |
Board Of Regents The University Of Texas System |
Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
|
WO2004020434A1
(ja)
|
2002-08-30 |
2004-03-11 |
Eisai Co., Ltd. |
含窒素芳香環誘導体
|
GB0223380D0
(en)
|
2002-10-09 |
2002-11-13 |
Astrazeneca Ab |
Combination therapy
|
KR20050051688A
(ko)
|
2002-10-09 |
2005-06-01 |
코산 바이오사이언시즈, 인코포레이티드 |
에포틸론(Еpo) D + 5-플루오로우라실(FU)/겜시타빈
|
WO2004035052A1
(ja)
|
2002-10-16 |
2004-04-29 |
Takeda Pharmaceutical Company Limited |
安定な固形製剤
|
JP4749660B2
(ja)
|
2002-10-16 |
2011-08-17 |
武田薬品工業株式会社 |
安定な固形製剤
|
DE60305724T2
(de)
|
2002-10-21 |
2006-11-09 |
Warner-Lambert Co. Llc |
Tetrahydrochinolin-derivate als crth2 antagonisten
|
WO2004039782A1
(ja)
|
2002-10-29 |
2004-05-13 |
Kirin Beer Kabushiki Kaisha |
Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
|
DE10250711A1
(de)
|
2002-10-31 |
2004-05-19 |
Degussa Ag |
Pharmazeutische und kosmetische Zubereitungen
|
MXPA05004919A
(es)
|
2002-11-06 |
2005-08-18 |
Cyclacel Ltd |
Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
|
GB0226434D0
(en)
|
2002-11-13 |
2002-12-18 |
Astrazeneca Ab |
Combination product
|
ITSV20020056A1
(it)
|
2002-11-14 |
2004-05-15 |
Alstom Transp Spa |
Dispositivo e metodo di verifica di motori software logici di comando di impianti ferroviari, in particolare di impianti di stazione
|
AR042042A1
(es)
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
ES2387909T3
(es)
|
2003-01-14 |
2012-10-03 |
Cytokinetics, Inc. |
Compuestos, composiciones y procedimientos de tratamiento de la insuficiencia cardiaca
|
JP3581361B1
(ja)
|
2003-02-17 |
2004-10-27 |
株式会社脳機能研究所 |
脳活動測定装置
|
US20040162333A1
(en)
|
2003-02-19 |
2004-08-19 |
Naima Mezaache |
Rapid absorption selective 5-HT agonist formulations
|
ES2401330T3
(es)
|
2003-02-26 |
2013-04-18 |
Sugen, Inc. |
Compuesto de heteroarilamino inhibidores de proteín quinasas
|
WO2004078144A2
(en)
|
2003-03-05 |
2004-09-16 |
Celgene Corporation |
Diphenylethylene compounds and uses thereof
|
ATE508747T1
(de)
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-kit kinase-hemmer
|
US7435590B2
(en)
|
2003-03-14 |
2008-10-14 |
Taisho Pharmaceutical Co., Ltd. |
Monoclonal antibody and hybridoma producing the same
|
AU2004220225B2
(en)
|
2003-03-14 |
2010-06-17 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
|
EA200501552A1
(ru)
|
2003-04-02 |
2006-04-28 |
Плива-Истраживанье И Развой Д.О.О. |
Фармацевтические композиции с менее выраженным горьким вкусом
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
WO2004101526A1
(ja)
*
|
2003-04-22 |
2004-11-25 |
Eisai Co., Ltd. |
4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキサミドの多形結晶及びその製造方法
|
EP1473043A1
(en)
|
2003-04-29 |
2004-11-03 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
|
US7107104B2
(en)
|
2003-05-30 |
2006-09-12 |
Medtronic, Inc. |
Implantable cortical neural lead and method
|
JP2005008534A
(ja)
|
2003-06-17 |
2005-01-13 |
Soc De Conseils De Recherches & D'applications Scientifiques (Scras) |
抗癌剤及び癌の治療方法
|
BRPI0412426A
(pt)
|
2003-07-10 |
2006-09-05 |
Astrazeneca Ab |
uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente
|
ATE395052T1
(de)
|
2003-08-15 |
2008-05-15 |
Ab Science |
Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
|
WO2005021537A1
(en)
|
2003-08-21 |
2005-03-10 |
Osi Pharmaceuticals, Inc. |
N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
|
US7485658B2
(en)
|
2003-08-21 |
2009-02-03 |
Osi Pharmaceuticals, Inc. |
N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
|
US7521448B2
(en)
|
2003-08-21 |
2009-04-21 |
Osi Pharmaceuticals, Inc. |
N-substituted benzimidazolyl c-Kit inhibitors
|
US7312243B1
(en)
|
2003-08-29 |
2007-12-25 |
Jay Pravda |
Materials and methods for treatment of gastrointestinal disorders
|
CN1856327A
(zh)
|
2003-09-23 |
2006-11-01 |
诺瓦提斯公司 |
Vegf受体抑制剂与化疗剂的组合
|
WO2005030140A2
(en)
|
2003-09-26 |
2005-04-07 |
Exelixis, Inc. |
C-met modulators and methods of use
|
KR200340552Y1
(ko)
|
2003-10-08 |
2004-02-11 |
주식회사 엘지화학 |
창틀 내부에 블라인드 및 방범창 설치가 용이한 이중창틀
|
JP2005124034A
(ja)
|
2003-10-20 |
2005-05-12 |
Nippon Telegr & Teleph Corp <Ntt> |
発信者の特定及び発信者への呼び返しを可能とする回線設定方法
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
TW200529849A
(en)
|
2003-11-28 |
2005-09-16 |
Novartis Ag |
Diaryl urea derivatives in the treatment of protein kinase dependent diseases
|
US6984403B2
(en)
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
CA2552435A1
(en)
|
2003-12-05 |
2005-06-23 |
Compound Therapeutics, Inc. |
Inhibitors of type 2 vascular endothelial growth factor receptors
|
SI1698623T1
(sl)
|
2003-12-25 |
2015-07-31 |
Eisai R&D Management Co., Ltd. |
Kristal soli 4-(3-kloro -4-(ciklopropilaminokarbonil)amino-fenoksi)-7- metoksi-6-kinolinkarboksamida ali njihov solvat in postopek njune proizvodnje
|
JP4932495B2
(ja)
|
2004-01-23 |
2012-05-16 |
アムゲン インコーポレイテッド |
化合物及び使用方法
|
NZ547517A
(en)
|
2004-02-27 |
2009-04-30 |
Eisai R&D Man Co Ltd |
Novel pyridine and pyrimidine derivatives for hepatocyte growth and tumour inihibition
|
KR20050091462A
(ko)
|
2004-03-12 |
2005-09-15 |
한국과학기술연구원 |
푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
EP1753723B1
(en)
|
2004-05-21 |
2008-08-13 |
Novartis Vaccines and Diagnostics, Inc. |
Substituted quinoline derivatives as mitotic kinesin inhibitors
|
KR100986945B1
(ko)
|
2004-06-03 |
2010-10-12 |
에프. 호프만-라 로슈 아게 |
젬시타빈 및 egfr-억제제로의 치료
|
CA2570501A1
(en)
|
2004-06-18 |
2006-01-26 |
Gergely Szakacs |
Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
|
US20050288290A1
(en)
|
2004-06-28 |
2005-12-29 |
Borzilleri Robert M |
Fused heterocyclic kinase inhibitors
|
US20050288521A1
(en)
|
2004-06-29 |
2005-12-29 |
Phytogen Life Sciences Inc. |
Semi-synthetic conversion of paclitaxel to docetaxel
|
CA2572331A1
(en)
|
2004-07-02 |
2006-02-09 |
Exelixis, Inc. |
C-met modulators and method of use
|
EP2364699A1
(en)
|
2004-09-13 |
2011-09-14 |
Eisai R&D Management Co., Ltd. |
Joint use of sulfonamide based compound with angiogenesis inhibitor
|
US7306807B2
(en)
|
2004-09-13 |
2007-12-11 |
Wyeth |
Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
EP1797881B1
(en)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medicinal composition with improved stability and reduced gelation properties
|
CA2581375A1
(en)
|
2004-09-27 |
2006-04-06 |
Kosan Biosciences Incorporated |
Specific kinase inhibitors
|
US20070298111A1
(en)
|
2004-10-01 |
2007-12-27 |
Eisai R&D Management Co., Ltd. |
Fine Particle-Containing Composition and Manufacturing Method Therefor
|
SG156668A1
(en)
|
2004-10-19 |
2009-11-26 |
Amgen Inc |
Angiopoietin-2 specific binding agents
|
WO2007040565A2
(en)
|
2004-11-22 |
2007-04-12 |
King Pharmaceuticals Research & Development, Inc. |
Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
|
US20070254930A1
(en)
|
2004-11-23 |
2007-11-01 |
Dong Wha Pharm. Ind. Co., Ltd. |
Oral Preparation Having Improved Bioavailability
|
CA2587642C
(en)
|
2004-11-30 |
2013-04-09 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
CN100341504C
(zh)
|
2004-12-01 |
2007-10-10 |
鲁南制药集团股份有限公司 |
佐米曲普坦速释制剂
|
EP1824843A2
(en)
|
2004-12-07 |
2007-08-29 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
AU2005319382B2
(en)
|
2004-12-21 |
2011-04-07 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
JP2006230816A
(ja)
|
2005-02-25 |
2006-09-07 |
H & A Investment:Kk |
サンダル用ホルダー
|
US20080286282A1
(en)
|
2005-02-28 |
2008-11-20 |
Eisai R & D Management Co., Ltd. |
Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor
|
CN101163468A
(zh)
|
2005-02-28 |
2008-04-16 |
卫材R&D管理有限公司 |
磺酰胺化合物的新联合用途
|
JP5106098B2
(ja)
|
2005-02-28 |
2012-12-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド化合物の抗癌剤との新規併用
|
US7221831B2
(en)
|
2005-03-03 |
2007-05-22 |
Nexans |
Multi-tube fiber optic cable and system and method for making the same
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
DK1883397T3
(da)
|
2005-05-17 |
2010-04-06 |
Actelion Pharmaceuticals Ltd |
Opløselig bosertan-tablet
|
JP2008545652A
(ja)
|
2005-05-17 |
2008-12-18 |
プレキシコン,インコーポレーテッド |
c−kitおよびc−fms活性を調節する化合物およびその用途
|
ES2371397T3
(es)
|
2005-06-22 |
2011-12-30 |
Plexxikon, Inc. |
Derivados de pirrolo[2,3-b]piridina como inhibidores de proteínas cinasas.
|
AU2006260148B9
(en)
|
2005-06-23 |
2009-09-17 |
Eisai R&D Managment Co., Ltd. |
Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)- 7-methoxy-6-quinolinecarboxamide and process for producing the same
|
US7550483B2
(en)
|
2005-06-23 |
2009-06-23 |
Eisai R&D Management Co., Ltd. |
Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
|
US20090305994A1
(en)
|
2005-06-29 |
2009-12-10 |
D Andrea Lucas Domenico |
Compounds Modulating Vegf Receptor and Uses Thereof
|
EA015535B1
(ru)
|
2005-07-11 |
2011-08-30 |
Никомед Данмарк Апс |
Формуляция бензимидазола
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
WO2007014335A2
(en)
|
2005-07-27 |
2007-02-01 |
The University Of Texas System |
Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
|
EP1925941B1
(en)
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
KR100950737B1
(ko)
|
2005-08-24 |
2010-03-31 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
신규 피리딘 유도체 및 피리미딘 유도체(3)
|
KR100990590B1
(ko)
|
2005-09-01 |
2010-10-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
붕해성이 개선된 의약 조성물의 제조 방법
|
CN1308012C
(zh)
|
2005-11-02 |
2007-04-04 |
广州中医药大学第二附属医院 |
一种治疗脑出血的中药组合物及其制备方法
|
KR101353763B1
(ko)
|
2005-11-07 |
2014-01-21 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용
|
US20090247576A1
(en)
|
2005-11-22 |
2009-10-01 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
CA2632286C
(en)
|
2005-12-05 |
2011-11-15 |
Pfizer Products Inc. |
Use of (r)-3-[1-(2,6-dichloro-3-fluror-phenyl)-ethoxyl]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine for treatment of cancer
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
KR100728926B1
(ko)
|
2006-03-20 |
2007-06-15 |
삼성전자주식회사 |
3축 힌지 구조를 갖는 휴대용 전자기기
|
CN101443009A
(zh)
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
CA2661333C
(en)
|
2006-08-23 |
2014-08-05 |
Eisai R&D Management Co., Ltd. |
Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
US7790885B2
(en)
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
KR20090048644A
(ko)
|
2006-09-07 |
2009-05-14 |
아스트라제네카 아베 |
Ret 수용체 티로신 키나아제를 타겟으로 하는 약물 치료를 위한 환자 평가 방법
|
EP2460520B1
(en)
|
2006-10-12 |
2015-09-30 |
PTC Therapeutics, Inc. |
Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
|
JP2009184925A
(ja)
|
2006-11-02 |
2009-08-20 |
Dai Ichi Seiyaku Co Ltd |
5−(1h−1,2,3−トリアゾール−4−イル)−1h−ピラゾール誘導体
|
KR20090108086A
(ko)
|
2007-01-19 |
2009-10-14 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
췌장암 치료용 조성물
|
AU2008206045A1
(en)
|
2007-01-19 |
2008-07-24 |
Ardea Biosciences, Inc. |
Inhibitors of MEK
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
EP2119706A4
(en)
|
2007-02-23 |
2011-04-27 |
Eisai R&D Man Co Ltd |
PYRIDINE OR PYRIMIDINE DERIVATIVITY WITH EXCELLENT CELL GROWTH-INHIBITORY EFFECT AND EXCELLENT ANTITUMOR EFFECT ON A CELL STRAIN WITH AN AMPLIFIED HGFR GENE
|
CA2680122A1
(en)
|
2007-03-05 |
2008-09-18 |
Kyowa Hakko Kirin Co., Ltd. |
Pharmaceutical composition
|
KR20090116794A
(ko)
|
2007-03-05 |
2009-11-11 |
교와 핫꼬 기린 가부시키가이샤 |
의약 조성물
|
GB2448181B
(en)
|
2007-04-05 |
2011-11-09 |
Ford Global Tech Llc |
Vehicle headlight beam controls
|
US7807172B2
(en)
|
2007-06-13 |
2010-10-05 |
University Of Washington |
Methods and compositions for detecting thyroglobulin in a biological sample
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
WO2009007748A2
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
CA2924418A1
(en)
|
2007-07-30 |
2009-02-05 |
Jean-Michel Vernier |
Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
|
JP5638244B2
(ja)
|
2007-11-09 |
2014-12-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
WO2009096377A1
(ja)
|
2008-01-29 |
2009-08-06 |
Eisai R & D Management Co., Ltd. |
血管阻害物質とタキサンとの併用
|
GB2456907A
(en)
|
2008-01-30 |
2009-08-05 |
Astrazeneca Ab |
Method for determining subsequent VEGFR2 inhibitor therapy comprising measuring baseline VEGF level.
|
US20110158983A1
(en)
|
2008-03-05 |
2011-06-30 |
Newell Bascomb |
Compositions and methods for mucositis and oncology therapies
|
US8044240B2
(en)
|
2008-03-06 |
2011-10-25 |
Ardea Biosciences Inc. |
Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
BRPI0911297A2
(pt)
|
2008-04-14 |
2019-09-24 |
Ardea Biosciences Inc |
composição e métodos para preparo e uso das mesmas
|
WO2009137649A2
(en)
|
2008-05-07 |
2009-11-12 |
The Trustees Of The University Of Pennsylvania |
Methods for treating thyroid cancer
|
EP2288383A1
(en)
|
2008-05-14 |
2011-03-02 |
Amgen, Inc |
Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
|
WO2009150256A1
(en)
|
2008-06-13 |
2009-12-17 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Markers for predicting response and survival in anti-egfr treated patients
|
CN102089007B
(zh)
|
2008-07-11 |
2013-05-15 |
诺瓦提斯公司 |
(a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品
|
US20110257035A1
(en)
|
2008-10-21 |
2011-10-20 |
Bayer Healthcare Llc |
Identification of signature genes associated with hepatocellular carcinoma
|
WO2010086964A1
(ja)
|
2009-01-28 |
2010-08-05 |
株式会社 静岡カフェイン工業所 |
がん治療のための併用療法
|
US20120164148A1
(en)
|
2009-08-07 |
2012-06-28 |
The Wistar Institute |
Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer
|
SI2468281T1
(sl)
|
2009-08-19 |
2016-05-31 |
Eisai R&D Management Co., Ltd. |
Farmacevtski sestavki, ki vsebujejo derivate kinolina
|
CA2771606A1
(en)
|
2009-08-21 |
2011-02-24 |
Mount Sinai School Of Medicine Of New York University |
Methods of using cd44 fusion proteins to treat cancer
|
EP2293071A1
(en)
|
2009-09-07 |
2011-03-09 |
Universität Zu Köln |
Biomarker for colorectal cancer
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
KR20130091331A
(ko)
*
|
2010-07-16 |
2013-08-16 |
교와 핫꼬 기린 가부시키가이샤 |
함질소 방향족 복소환 유도체
|
SG187119A1
(en)
|
2010-07-19 |
2013-02-28 |
Hoffmann La Roche |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
KR20130091750A
(ko)
|
2010-07-19 |
2013-08-19 |
에프. 호프만-라 로슈 아게 |
유방암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
|
AU2011281700B2
(en)
|
2010-07-19 |
2017-02-09 |
F. Hoffmann-La Roche Ag |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
WO2012019300A1
(en)
|
2010-08-10 |
2012-02-16 |
Siu K W Michael |
Endometrial cancer biomarkers and methods of identifying and using same
|
US20120077837A1
(en)
|
2010-09-24 |
2012-03-29 |
Eisai R&D Management Co., Ltd. |
Anti-tumor agent
|
MY181439A
(en)
|
2011-02-28 |
2020-12-22 |
Sunshine Lake Pharma Co Ltd |
Substituted quinoline compounds and methods of use
|
US20120244209A1
(en)
|
2011-03-02 |
2012-09-27 |
Roth Jack A |
Tusc2 therapies
|
JP6322413B2
(ja)
|
2011-03-10 |
2018-05-09 |
プロヴェクタス ファーマテック,インク. |
改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
|
WO2012131297A1
(en)
|
2011-03-28 |
2012-10-04 |
Jonathan Bayldon Baell |
Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use
|
EP2700403B1
(en)
|
2011-04-18 |
2015-11-25 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
WO2012154935A1
(en)
|
2011-05-12 |
2012-11-15 |
Eisai R&D Management Co., Ltd. |
Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
|
ES2622401T3
(es)
|
2011-05-17 |
2017-07-06 |
Eisai R&D Management Co., Ltd. |
Método de predicción de la eficacia de un inhibidor de la angiogénesis
|
EP2714937B1
(en)
|
2011-06-03 |
2018-11-14 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
PE20190262A1
(es)
|
2011-08-01 |
2019-02-25 |
Genentech Inc |
Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
EP2849784A1
(en)
|
2012-05-16 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
|
KR102130865B1
(ko)
|
2012-10-02 |
2020-08-05 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물
|
MX2015007185A
(es)
|
2012-12-04 |
2017-09-05 |
Eisai R&D Man Co Ltd |
Uso de eribulina en el tratamiento de cancer de pecho.
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
RU2659219C2
(ru)
|
2013-02-28 |
2018-06-29 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
ТЕТРАГИДРОИМИДАЗО[1,5-d][1,4]ОКСАЗЕПИНОВОЕ ПРОИЗВОДНОЕ
|
ES2687968T3
(es)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
|
KR102265952B1
(ko)
|
2013-06-26 |
2021-06-16 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
|
US9174998B2
(en)
|
2013-12-25 |
2015-11-03 |
Eisai R&D Management Co., Ltd. |
(6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
NZ722891A
(en)
|
2014-02-04 |
2021-07-30 |
Incyte Corp |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
HRP20221047T1
(hr)
*
|
2014-08-28 |
2022-11-11 |
Eisai R&D Management Co., Ltd. |
Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
RU2729936C2
(ru)
|
2015-06-16 |
2020-08-13 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противораковое средство
|
SG11201709593VA
(en)
|
2015-06-23 |
2017-12-28 |
Eisai R&D Man Co Ltd |
CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
|
US20200375975A1
(en)
|
2016-04-15 |
2020-12-03 |
Eisai R&D Management Co., Ltd. |
Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus
|
CN107305202B
(zh)
|
2016-04-22 |
2020-04-17 |
北京睿创康泰医药研究院有限公司 |
分析甲磺酸乐伐替尼及其制剂杂质的hplc方法及杂质作参比标准的用途
|
JP6581320B2
(ja)
|
2017-02-08 |
2019-09-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|